The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation

Silvia Martini, Maria Francesca Donato, Chiara Mazzarelli, Maria Rendina, Ubaldo Visco-Comandini, Daniela Filì, Alice Gianstefani, Stefano Fagiuoli, Mario Melazzini, Simona Montilla, Luca Pani, Sandra Petraglia, Pierluigi Russo, Maria Paola Trotta, Paola Carrai, Paolo Caraceni, ITACOPS study group

Research output: Contribution to journalArticle

Abstract

BACKGROUND & AIMS: This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program.METHODS: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks.RESULTS: Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for
Original languageEnglish
JournalLiver International
DOIs
Publication statusPublished - Sep 16 2017

    Fingerprint

Keywords

  • Journal Article

Cite this

Martini, S., Donato, M. F., Mazzarelli, C., Rendina, M., Visco-Comandini, U., Filì, D., Gianstefani, A., Fagiuoli, S., Melazzini, M., Montilla, S., Pani, L., Petraglia, S., Russo, P., Trotta, M. P., Carrai, P., Caraceni, P., & group, ITACOPS. S. (2017). The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation. Liver International. https://doi.org/10.1111/liv.13588